Derik De Bruin
Stock Analyst at B of A Securities
(3.67)
# 763
Out of 5,147 analysts
223
Total ratings
65.77%
Success rate
16.24%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Maintains: Neutral | $410 → $350 | $319.38 | +9.59% | 15 | Feb 10, 2026 | |
| BRKR Bruker | Maintains: Buy | $43 → $60 | $40.11 | +49.59% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $121.38 | +35.94% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,366.69 | +1.71% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $210.64 | +4.44% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $54.59 | -50.54% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $98.31 | +11.89% | 3 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $23.05 | -43.60% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $49.80 | +1.37% | 6 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $4.61 | +138.61% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $103.38 | -37.13% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $9.83 | +62.77% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $521.11 | +26.65% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $178.81 | +31.42% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $178.49 | +17.65% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $254.34 | +39.58% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $15.52 | +67.53% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $289.12 | -6.27% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $211.91 | -14.11% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $10.72 | +95.90% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $12.06 | +165.34% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $134.46 | -25.63% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $75.36 | +14.12% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.40 | +282.35% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.72 | +277.91% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $108.14 | +140.43% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $6.75 | +1,677.78% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $131.10 | -8.47% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.93 | +366.32% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $656.73 | -64.22% | 3 | Nov 2, 2018 |
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $410 → $350
Current: $319.38
Upside: +9.59%
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $40.11
Upside: +49.59%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $121.38
Upside: +35.94%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,366.69
Upside: +1.71%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $210.64
Upside: +4.44%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $54.59
Upside: -50.54%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $98.31
Upside: +11.89%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $23.05
Upside: -43.60%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $49.80
Upside: +1.37%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $4.61
Upside: +138.61%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $103.38
Upside: -37.13%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $9.83
Upside: +62.77%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $521.11
Upside: +26.65%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $178.81
Upside: +31.42%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $178.49
Upside: +17.65%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $254.34
Upside: +39.58%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $15.52
Upside: +67.53%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $289.12
Upside: -6.27%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $211.91
Upside: -14.11%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $10.72
Upside: +95.90%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $12.06
Upside: +165.34%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $134.46
Upside: -25.63%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $75.36
Upside: +14.12%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.40
Upside: +282.35%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.72
Upside: +277.91%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $108.14
Upside: +140.43%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $6.75
Upside: +1,677.78%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $131.10
Upside: -8.47%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.93
Upside: +366.32%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $656.73
Upside: -64.22%